DE69730313D1 - METHOD FOR INACTIVATING RAS SUB-FAMILY PROTEINS AND COMPOUNDS THEREFOR - Google Patents

METHOD FOR INACTIVATING RAS SUB-FAMILY PROTEINS AND COMPOUNDS THEREFOR

Info

Publication number
DE69730313D1
DE69730313D1 DE69730313T DE69730313T DE69730313D1 DE 69730313 D1 DE69730313 D1 DE 69730313D1 DE 69730313 T DE69730313 T DE 69730313T DE 69730313 T DE69730313 T DE 69730313T DE 69730313 D1 DE69730313 D1 DE 69730313D1
Authority
DE
Germany
Prior art keywords
ras
sub
family proteins
compounds therefor
inactivating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730313T
Other languages
German (de)
Other versions
DE69730313T2 (en
Inventor
Eichel-Streiber Christoph Von
Patrice Boquet
Monica Thelestam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of DE69730313D1 publication Critical patent/DE69730313D1/en
Application granted granted Critical
Publication of DE69730313T2 publication Critical patent/DE69730313T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method of treating a disorder characterized by an activating mutation in a Ras proto-oncogene, comprising contacting cells of a patient suffering from the disorder with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivation of Ras by glucosylation of Ras' threonine 35 in said cell. The protein preferably is an immunotoxin that contains as a toxic domain the catalytic domain of toxin LT.
DE69730313T 1996-02-02 1997-01-31 METHOD OF INACTIVATING PROTEINS OF THE RAS UNDERFAMILY AND COMPOUNDS THEREOF Expired - Lifetime DE69730313T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96101469 1996-02-02
EP96101469 1996-02-02
PCT/EP1997/000426 WO1997027871A1 (en) 1996-02-02 1997-01-31 Method of inactivation of ras subfamily proteins and agents therefor

Publications (2)

Publication Number Publication Date
DE69730313D1 true DE69730313D1 (en) 2004-09-23
DE69730313T2 DE69730313T2 (en) 2005-09-01

Family

ID=8222454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730313T Expired - Lifetime DE69730313T2 (en) 1996-02-02 1997-01-31 METHOD OF INACTIVATING PROTEINS OF THE RAS UNDERFAMILY AND COMPOUNDS THEREOF

Country Status (9)

Country Link
US (1) US6849715B2 (en)
EP (1) EP0877622B1 (en)
AT (1) ATE273712T1 (en)
AU (1) AU1598297A (en)
DE (1) DE69730313T2 (en)
DK (1) DK0877622T3 (en)
ES (1) ES2227667T3 (en)
PT (1) PT877622E (en)
WO (1) WO1997027871A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039491A2 (en) * 2003-10-22 2005-05-06 The John Hopkins University Certain improved combination bacteriolytic therapy for the treatment of tumors
DE602004025834D1 (en) 2003-10-22 2010-04-15 Univ Johns Hopkins THE TREATMENT OF TUMORS
US10829752B2 (en) 2014-08-01 2020-11-10 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694296B1 (en) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibiting the activity of ras proteins, preparation and use.
ATE240117T1 (en) * 1993-03-29 2003-05-15 Pfizer MULTI-COMPONENT CLOSTRIDIAL VACCINE USING SAPONIN AS AN ADJUVANT

Also Published As

Publication number Publication date
EP0877622B1 (en) 2004-08-18
EP0877622A1 (en) 1998-11-18
AU1598297A (en) 1997-08-22
US20030103987A1 (en) 2003-06-05
US6849715B2 (en) 2005-02-01
WO1997027871A1 (en) 1997-08-07
ES2227667T3 (en) 2005-04-01
PT877622E (en) 2005-01-31
ATE273712T1 (en) 2004-09-15
DE69730313T2 (en) 2005-09-01
DK0877622T3 (en) 2004-12-20

Similar Documents

Publication Publication Date Title
DK0653911T3 (en) Methods for inactivating bacteria in blood preparations with the 8-methoxypsoralen
DE69328550D1 (en) USE OF FULLEREN DERIVATIVES IN DIAGNOSTIC AND / OR THERAPEUTIC AGENTS
ATE120239T1 (en) SYSTEM AND CONTINUOUS PROCESS FOR THE BIOCATALYTIC DESULFURIZATION OF SULFUR-CONTAINING HETEROCYCLIC MOLECULES.
DE69421778D1 (en) Use of effective amounts of active substances for the treatment of combination skin
ATE319823T1 (en) BMP-12, BMP-13 AND TENDON-INDUCING COMPOSITIONS CONTAINING SAME
ES532075A0 (en) PROCEDURE FOR THE INACTIVATION OF PATHOGENIC GERMS, CAPABLE OF REPRODUCING
DE3674941D1 (en) OZONE DISINFECTION OF BLOOD AND BLOOD PRODUCTS.
DE69435321D1 (en) Use of botulinum toxin for the treatment of myofascial pain syndrome
ATE154643T1 (en) 3-AMINOPYRAZOLO-HETEROCYCLES, THEIR USE FOR THE DETERMINATION OF HYDROGEN PEROXIDE, HYDROGEN PEROXIDE-FORMING SYSTEMS, PEROXIDASE, PEROXIDATICALLY EFFECTIVE SUBSTANCES OR ELECTRON-RICH AROMATIC COMPOUNDS, CORRESPONDING DETERMINATION METHODS AND SUITABLE FOR THIS NICE MEANS
DE58904683D1 (en) PREPARATION WITH ANTI-CORE PERACTIVITY AND WIDE RANGE OF EFFECTS, SUBSTANCES CONTAINING OR CONTAINING THEM AND THE USE THEREOF FOR THE TREATMENT OF BACTERIAL OR TOXINE-RELATED DISEASES AND FOR THE POTENTIAL OF PROTECTION.
ATE209909T1 (en) USE OF TACHYKININ ANTAGONISTS TO TREAT VOMITING
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
Adams Regeneration and the kinetics of peroxidase inactivation
DE69730313D1 (en) METHOD FOR INACTIVATING RAS SUB-FAMILY PROTEINS AND COMPOUNDS THEREFOR
DE3889783T2 (en) Use of antibody-antigen interaction to protect or modulate biological activity.
DE69308879D1 (en) METHOD FOR THE TREATMENT OF WASTE COMBUSTION RESIDUES AND THE USE THEREOF AS AN ADSORPTION AGENT
NO984189L (en) Procedure for the treatment of bipolar disorder
DE69936779D1 (en) USE OF NGALI NUTH OIL FOR THE TREATMENT / REDUCTION OF ARTHRITISERIAL ANSWERS AND OTHER SIMILAR INTERFERENCE
ES2077707T3 (en) PROCEDURE FOR THE INACTIVATION OF THE BIOLOGICAL ACTIVITY OF DNA.
ATE205396T1 (en) USE OF HUMAN PROTEIN C TO PREVENT AND TREAT THROMBOCYTE DEPOSITS
DE69711422T2 (en) USE OF (R) -VERAPAMIL AS A MEDICINE FOR TREATING ANGINA
DE69932592D1 (en) RECOMBINANT PROTEINS DERIVED FROM HGF AND MSP
DE69825307D1 (en) USE OF PROTEIN H AS A CYTOSTATIC ACTIVE SUBSTANCE
DE59407576D1 (en) Use of etofibrate and pharmaceutical compositions containing etofibrate for the treatment of diabetic angio- and retinopathy
DE59708286D1 (en) USE OF ACTIVE SUBSTANCE MIXTURES CONTAINING PHYTOSTENOLS AND / OR PHYTOSTENOLESTERS AND POTENTIATING AGENTS FOR THE PRODUCTION OF HYPOCHOLESTERINEMIC AGENTS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation
8327 Change in the person/name/address of the patent owner

Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE